(CBIO) |
| 0 (0%) 06-12 22:12 |
| Open: | |
| High: | |
| Low: | |
| Volume: | 0 |
| Market Cap: | 0(M) |
| PE Ratio: | 0 |
| Exchange: | |
| Industry: | |
| Sector: |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 22.49 |
| Resistance 1: | 20.25 |
| Pivot price: | 18.95 |
| Support 1: | 16.63 |
| Support 2: | 13.84 |
| 52w High: | |
| 52w Low: |
Financials
| EPS | 0.000 |
| Book Value | 0.000 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.393 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | -2.00 |
| Return on Assets (ttm) | 380.1 |
| Return on Equity (ttm) | 0.0 |
Company news
Thu, 11 Jun 2026
Crescent Biopharma gives two new hires 23,550 stock options - Stock Titan
Mon, 08 Jun 2026
CBIO: CR-001 and ADC combinations target a $100B+ oncology market, with pivotal data expected in 2027 - TradingView
Mon, 08 Jun 2026
CBIO: CR-001 and ADC pipeline aim for best-in-class oncology therapies, with pivotal data expected from 2027 - TradingView
Mon, 08 Jun 2026
HC Wainwright & Co. Initiates Coverage of Crescent Biopharma (CBIO) with Buy Recommendation - MSN
Thu, 04 Jun 2026
Brazilian CBIO prices hit lowest level in Platts series - S&P Global
Wed, 03 Jun 2026
Fairmount-linked director awarded 11,050 CBIO options at $17.01 exercise price - Stock Titan
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
